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baseline showed improvement in severity of regurgitation. Patients with moderate MR
or above demonstrated the greatest improvement.
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Background: Transcatheter aortic valve implantation (TAVI) is an established
treatment alternative to surgical aortic valve replacement in high-risk and inoperable
patients and outcomes among patients with intermediate risk remain to be determined.
The aim of this study was to assess clinical outcomes among Asian patients with low
to intermediate risk undergoing TAVI.
Methods: Data from Asian TAVI multicenter registry were pooled and analyzed. In
total, 185 patients with severe symptomatic aortic stenosis undergoing TAVI were
categorized according to the Society of Thoracic Surgeons (STS) score into low (STS
< 3%; N ¼ 82, 44.3%), intermediate (STS  3% and  8%; N ¼ 77, 41.6%), and
high risk (STS > 8%; N ¼ 26, 14.1%) groups.
Results: Signiﬁcant differences were found between the groups (low risk vs. interme-
diate risk vs. high risk) for age (75.6 5.5 vs. 80.5 5.2 vs. 80.1 6.7, p< 0.001), body
mass index (25. 5  3.1 vs. 23.6  3.7 vs. 23.2  3.1, p ¼ 0.001), diabetes (21.3% vs.
46.7% vs. 68.4%, p < 0.001), previous coronary artery bypass surgery (1.3% vs. 6.7%
vs. 21.1%, p ¼ 0.004), and peripheral artery disease (4.0% vs. 8.3% vs. 42.1%, p <
0.001). No differences were observed with regards to major vascular complication,
postoperative aortic regurgitation  moderate, new permanent pacemaker, device suc-
cess and all-cause mortality at 30 days, however signiﬁcant difference was found for all-
cause mortality at 1-year (2.5% vs. 11.3% vs. 17.9%, p ¼ 0.043).
Conclusions: Compared with patients at high risk, patients with low or intermediate
risk have favorable clinical outcomes after TAVI in the Asian population.B228 JACC Vol 64/11/Suppl B j SepTCT-781
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Background: Vascular and bleeding complications are common following trans-
catheter aortic valve replacement (TAVR). The impact of the expandable sheath (e-
sheath) for trans-femoral Edwards aortic valve replacement is unclear. Our objective
was to compare the incidence of procedural complication when using 18Fr ﬁxed size
sheath vs. 16 to 18Fr e-sheath during TAVR.
Methods: We enrolled 90 consecutive patients who underwent TAVR with
Edwards valve at our center. Since June 2011 e-sheath has been routinely
employed to obtain femoral access. Prostar System for vascular hemostasis, and
intraprocedural heparin monitored by activated clotting time were used in all
cases. We compared baseline and procedural outcomes according to the use of
e-sheath. Vascular and bleeding complications were deﬁned using the VARC-2
deﬁnitions.
Results: Patients receiving e-sheath (n¼54, 60%) matched for age, sex, body mass
index, rate of peripheral artery disease, diabetes, and chronic kidney disease compared
to those treated with ﬁxed size sheath. E-sheath use was associated with reductions in
major or life-threatening bleeding (5.6% vs. 39%, p< 0.001) and minor vascular
complication (24% vs. 39%, p¼0.31), while major vascular complication (7.4% vs.
5.6%, p¼0.73), and procedural mortality (0.0% vs 2.7%, p¼0.21) resulted not
signiﬁcantly different (Figure 1).Conclusions: The use of e-sheath is associated with substantial reductions in bleeding
and minor vascular bleeding, during trans-femoral TAVR, while an advantage in term
of major vascular complication was not readily apparent.
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Background: Serious vascular complications have been reported to occur in 6% of
the transfemoral TAVI patients. The aim was to report access site related complica-
tions using Single (SP) versus Double (DP) Prostar XL for closure of 18F femoral
arterial access in TAVI.
Methods: 134 patients included in our prospective TAVI database at Karolinska
University Hospital (Nov 2012- Feb 2014), transfemoral-TAVI was performed in
126 patients using 18F sheath. The ﬁrst 63 consecutive patients were treated with
SP and the last 63 patients with DP closure. Primary endpoint was deﬁned as ac-
cess-site related vascular complication (femoral hematoma >4 cm in diameter,
external femoral bleeding, retroperitoneal hematoma or blood transfusion within
1 week after the procedure). Secondary endpoint was deﬁned as post-procedure
hemoglobin (Hb)-fall.tember 13–17, 2014 j TCT Abstracts/Valvular disease - Aortic: TAVR
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8  5.8 and 82% being in NYHA class III or IV. The CoreValve aortic valve pros-
thesis was used in all patients, and all procedures were done without general anes-
thesia. No differences were found between SP and DP group in clinical and procedural
characteristics. Primary endpoint occurred in 25% (n¼16) of the SP patients and in 5%
(n¼3) of DP patients (p< 0.001) (Figure). Postprocedure Hb-fall was 20.0 g/L ( 13)
in the SP and 14.3 g/L ( 8) in the DP group (p< 0,005).Conclusions: The double Prostar XL large arterial closure technique during TAVI
was associated with less access-site related vascular complication and less blood loss
compared with single Prostar XL.
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Background: We have previously demonstrated the safety and efﬁcacy of our hybrid
closure (HC) technique which employs the combination of 1 “pre-closed” Perclose (P)
suture mediated vascular closure device (VCD) followed by the deployment of a 6
French (Fr) Mynx or 6 Fr Angioseal to effect hemostasis in up to 14 Fr arteriotomies
(AR) in patients undergoing high risk coronary intervention with Impella 2.5 or CP
support via the common femoral artery (CFA). We further sought to determine if this
method could also reliably achieve hemostasis in the setting of transfemoral (TF)
transcatheter aortic valve replacement (TAVR) utilizing an expandable sheath (e-
sheath) with an outer diameter of 16Fr and in the setting of the use of alternate large
bore AR sites, namely the axillary artery (AA).
Methods: 4 patients undergoing TF-TAVR and 1 patient undergoing high risk PCI
with Impella 2.5 support inserted via the left axillary artery (AA) due to severe pe-
ripheral vascular disease had their large bore AR closed in the following manner. Post-
procedure, the 16 Fr e-sheath or 13 Fr Impella sheath was removed and a 0.035” wire
was inserted into the vessel through the sheath. As the sheath was withdrawn the
vessel was “partially pre-closed” with 1 P device. For the 16 Fr AR, an 8 Fr sheath
was advanced over the 0.035 wire achieving temporary hemostasis, and effectively
reducing a 16Fr to a 8Fr AR site. The 8Fr AR site was then simply closed with an 8 Fr
Angioseal vascular closure device. For the 13 Fr AR in the left AA a 6 Fr sheath was
inserted after deployment of the P and a 6 Fr sheath and angioseal VCD used. An-
giograms of all AR sites were performed after HC. Follow up was done the next day
and at 30 days.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/VaResults: Hybrid closure was successful in achieving complete hemostasis in all 4 TF-
TAVR cases and in the high-risk Impella supported PCI via the left AA. All patients
who underwent HC were free of complications at day 1 and 30 post-procedure.
Conclusions: HC is a simple and safe alternative to the traditional “pre-close” tech-
nique. HC is also reliable in effecting hemostasis in patients undergoing TF-TAVR
and in closure of large bore AR of the AA. Larger studies are needed to validate our
ﬁndings.
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Background: Direct comparison of transfemoral (TF) and transapical (TA) accesses
for Transcatheter Aortic Valve Replacement (TAVR) is troublesome due to hetero-
geneity in outcome deﬁnitions between studies. We used applied standardized Valve
Academic Research Consortium (VARC) deﬁnition of vascular complications to
perform an updated meta-analysis for patients receiving Edwards SAPIEN TAVR via
TF and TA approaches.
Methods: Pubmed and Scopus databases were searched for studies that compared the
incidence of major vascular complications in TF and TA accesses in Edwards SA-
PIEN TAVR procedures. Random-effects model was used to calculate the relative
risk. Heterogeneity was assessed with Higgins and Thompson I2 statistic. All analyses
were performed using STATA 11.2 (Texas, USA).
Results: Fourteen studies met all inclusion criteria. A total of 2,526 patients were
included, of which 1,337 (52.9%) had TF TAVR. As illustrated in ﬁgure 1, the pooled
risk of major vascular complications with the TF access was signiﬁcantly higher than
the TA approach (17.2% x 5.2%, respectively; RR 2.94, 95% CI 2.08-4.14). This
difference was consistent among studies that predated VARC criteria (RR 3.18, 95%
CI 1.86-5.45) and those that adopted VARC standardized outcome deﬁnitions (RR
2.48; 95% CI 1.68-3.64).
Conclusions: In this updated meta-analysis, TF access was associated with a signif-
icantly higher incidence of 30-day major vascular complications when compared to
the TA technique. This difference persisted in studies that used standardized VARC
deﬁnitions.lvular disease - Aortic: TAVR B229
